Goodrx Holdings, Inc. Stock Price, News & Analysis

GoodRx (GDRX) has launched a new e-commerce platform, marking its entry into the over-the-counter (OTC) market. The platform debuts with Opill®, the first OTC daily birth control pill, allowing direct-to-consumer ordering with home delivery. This initiative addresses healthcare access gaps, particularly benefiting the 19 million women in areas with contraceptive services. The new platform enables consumer health and pharmaceutical brands to integrate their offerings directly within GoodRx's ecosystem, leveraging its extensive reach of over 25 million consumers and 750,000 healthcare professionals annually.

GoodRx (Nasdaq: GDRX) announced an exclusive partnership making QSYMIA, a once-daily oral weight management medication, available at a low cash price of $149 for a 30-day supply across 70,000+ retail pharmacies nationwide. The initiative aims to improve accessibility to obesity treatment, addressing a significant health concern affecting more than two in five U.S. adults. QSYMIA, designed to help manage hunger and reduce cravings, has shown that one in five adults and one in four young adults achieve at least 20% body weight loss on the top dose. This partnership extends GoodRx's momentum in weight loss solutions and broadens its portfolio of brand-name medication savings programs.

GoodRx Holdings announced the appointment of Ronald E. Bruehlman to its Board of Directors, effective November 8, 2024. Bruehlman, currently the CFO of IQVIA, brings 39 years of finance experience in healthcare services, industrial, and petroleum industries. He will serve as chairperson of the Board's Audit and Risk Committee, replacing Julie Bradley. Previously, Bruehlman served as CFO of IMS Health and held senior finance leadership roles at United Technologies for 23 years. The appointment aims to strengthen GoodRx's financial strategy and risk assessment capabilities as the company focuses on sustainable and profitable revenue growth.

GoodRx (NASDAQ: GDRX) has announced new affordability programs for menopause hormone therapies by Pfizer. Research shows menopause medication prices have increased by 58% since 2014. Through this initiative, eligible patients can access brand-name menopause hormone therapies for $99-$249 at over 70,000 pharmacies nationwide. The company has partnered with more than 150 brands and now has over 50 pharmaceutical brands offering cash price options on its platform. GoodRx reports having helped consumers save over $75 billion on prescription costs since 2011.

GoodRx (NASDAQ: GDRX), the leading prescription savings platform in the U.S., has announced a partnership with retail pharmacies to offer a pay-over-time option for select medications directly on the GoodRx platform. The program, launching with partner pharmacies including Hy-Vee, will allow approved users to select an Affirm payment plan when purchasing their prescriptions.

The new feature aims to provide consumers with financial flexibility and control, potentially helping them reach deductibles or access medications more easily. The process will be integrated into the GoodRx platform, allowing users to validate prescriptions, check inventory, and choose payment options before picking up their medications at local pharmacies.

This initiative is part of GoodRx's broader e-commerce strategy to simplify the prescription process for patients and retail pharmacies. The program is expected to roll out in the coming months, with the goal of improving medication adherence and removing healthcare barriers.

GoodRx Holdings, Inc. (Nasdaq: GDRX), the leading prescription savings platform in the U.S., has announced the date for its third quarter 2024 earnings release and conference call. The company will release its financial results on Thursday, November 7, 2024, before U.S. markets open. GoodRx management will hold a conference call and webcast at 5:00 a.m. Pacific Time (8:00 a.m. Eastern Time) on the same day to discuss the results and the Company's business outlook.

Interested parties can pre-register for the conference call using a provided link, which will give them dial-in details and a unique passcode. The call will also be webcast live on the Company's investor relations website. Accompanying materials will be posted prior to the conference call. An archived version of the webcast will be available on the investor relations website for at least 30 days after the live call.

GoodRx (Nasdaq: GDRX) has announced it is offering the lowest discounted cash price for neffy®, the first needle-free treatment for Type I allergic reactions, including anaphylaxis. Consumers can access a pack of two single-use neffy devices for $199 at over 70,000 pharmacies nationwide exclusively through GoodRx. neffy, approved by the FDA in August, delivers epinephrine nasally, providing an innovative alternative to auto-injectors.

This partnership with ARS Pharmaceuticals aims to enhance accessibility and affordability for millions of Americans affected by allergies. GoodRx's collaboration with nearly 150 brands across the healthcare industry demonstrates its commitment to providing cost-effective treatments and patient support programs.

GoodRx Holdings, Inc. (Nasdaq: GDRX), the leading prescription savings platform in the U.S., has announced its participation in two upcoming investor conferences. The company's executives will engage in fireside chats at:

• The Morgan Stanley 22nd Annual Global Healthcare Conference in New York, NY on September 5, 2024, at 7:45 a.m. ET
• The Wells Fargo 2024 Healthcare Conference in Boston, MA on September 6, 2024, at 8:00 a.m. ET

Both events will be livestreamed on GoodRx's Investor Relations website, with archived recordings available for at least 30 days after each conference.

GoodRx Holdings, Inc. (Nasdaq: GDRX) reported its Q2 2024 financial results, showing positive growth and profitability. Key highlights include:

- Revenue increased 6% to $200.6 million
- Net income of $6.7 million, with a 3.3% margin
- Adjusted EBITDA of $65.4 million, with a 32.6% margin
- Over 7 million consumers of prescription-related offerings

The company's guidance for Q3 2024 projects revenue between $193-197 million and an Adjusted EBITDA Margin of about 32%. For the full year 2024, GoodRx expects revenue at the lower end of $800-810 million, with Adjusted EBITDA over $255 million, up 17% from 2023.